Sobi, stated, "Today's approval highlights the robust clinical evidence supporting Aspaveli's effectiveness and safety, providing healthcare professionals and patients with an expanded arsenal for managing PNH. European patients can now begin treatment with Aspaveli upon diagnosis or transition from their current C5 inhibitor therapy if they exhibit signs of haemolytic anaemia. This significant milestone reflects our commitment to enhancing treatment options for those affected by this rare and complex condition."